UK Spinraza Data Review Shows Benefits Of NICE Flexibility
Executive Summary
Biogen has described as “exciting” a first-of-a-kind interim data review that has led to expanded recommendations for the company’s spinal muscular atrophy drug Spinraza.
You may also be interested in...
New Hope, Funding Approaches As Roche Brings Evrysdi To India
Roche’s Evrysdi debuts in India backed by a patient support program ahead of Novartis’ Zolgensma and Biogen’s Spinraza. Spotlights remains on the price tag for the SMA therapy amid hopes that novel approaches such as crowdfunding could also broaden access.
Roche To Work On Reversing English Funding Rejection For SMA Drug
Evrysdi could follow Spinraza and Zolgensma to become the third treatment for spinal muscular atrophy available on England’s National Health Service if Roche can agree on a lower price for the drug.
Can The UK Remain A First Launch Market?
More political support from the National Health Service and health ministers is needed to ensure the UK’s future as a desirable launch market.